Transthyretin Amyloidosis (ATTR)

Ionis Pharmaceuticals and AstraZeneca concluded the year 2023 on a positive note as they received the eagerly awaited approval from the FDA for their transthyretin amyloidosis (ATTR) medication, Wainua. In particular, the agency approved the use of the ligand-conjugated antisense oligonucleotide (LICA) medication f...

BridgeBio bags USD 299 Million for genetic diseases BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical development. Several therapeutic areas are being taken under the consideration of the pharma. Also, th...